Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Talaris Therapeutics, Inc. (TALS)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.4500+0.0100 (+0.69%)
At close: 04:00PM EST
1.4500 0.00 (0.00%)
After hours: 04:01PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Williams %R

Williams %R

Previous Close1.4400
Open1.4201
Bid1.4200 x 1000
Ask1.5000 x 1000
Day's Range1.4200 - 1.4700
52 Week Range1.1600 - 16.6300
Volume36,835
Avg. Volume205,803
Market Cap60.149M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.5110
Earnings DateNov 10, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.60
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for TALS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Talaris Therapeutics, Inc.
    Daily – Vickers Top Insider Picks for 09/07/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Rating
    Fair Value
    Economic Moat
    3 months agoArgus Research
View more
  • GlobeNewswire

    Talaris Therapeutics to Participate at the 5th Annual Evercore ISI HealthCONx Conference

    BOSTON and LOUISVILLE, Ky., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will participate in a fireside chat at the 5th Annual Evercore ISI HealthCONx Conference being held virtually on Tuesday, November 29, 2

  • GlobeNewswire

    Talaris Therapeutics Announces Third Quarter Financial Results and Corporate Update

    Enrollment and dosing continue in the Phase 3 FREEDOM-1 trial of FCR001 in living donor kidney transplant (LDKT) patients Two presentations at the 2022 American Society of Nephrology (ASN) Annual Meeting Strong cash balance with expected runway through 2024 BOSTON and LOUISVILLE, Ky., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ trans

  • GlobeNewswire

    Talaris Therapeutics Presents Data on Mechanisms of FCR001 Activity to Induce Immune Tolerance

    BOSTON and LOUISVILLE, Ky., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, presented new data characterizing the mechanisms of FCR001-induced immune tolerance in two oral presentations at the 2022 American Society of Nephrology (ASN) Annual Meeting. The first presentation reported o

Advertisement
Advertisement